Fig. 2.
Fig. 2. Survival days for the groups of mice immunized. / (A) HSP70. (B) GP96. Ten days after BMT, recipient mice were inoculated with 2.5 × 104 A20 cells (day 0). Mice were immunized on days 4, 9, 14, and 19. (A) Immunized with PBS (○), 20 μg HSP70 derived from A20 cells (▵), 40 μg HSP70 derived from A20 cells (■), and 40 μg HSP70 derived from liver (●). (B) Immunized with PBS (○), 2.5 μg GP96 derived from A20 cells (▴), 5 μg GP96 derived from A20 cells (▪), and 5 μg GP96 derived from liver (●). Mice immunized with HSP70 (A) or GP96 (B) derived from A20 had significantly enhanced survival. *P < .01 versus PBS, Wilcoxon test. There were 6 mice in each group. Data are representative of 3 separate experiments.

Survival days for the groups of mice immunized.

(A) HSP70. (B) GP96. Ten days after BMT, recipient mice were inoculated with 2.5 × 104 A20 cells (day 0). Mice were immunized on days 4, 9, 14, and 19. (A) Immunized with PBS (○), 20 μg HSP70 derived from A20 cells (▵), 40 μg HSP70 derived from A20 cells (■), and 40 μg HSP70 derived from liver (●). (B) Immunized with PBS (○), 2.5 μg GP96 derived from A20 cells (▴), 5 μg GP96 derived from A20 cells (▪), and 5 μg GP96 derived from liver (●). Mice immunized with HSP70 (A) or GP96 (B) derived from A20 had significantly enhanced survival. *P < .01 versus PBS, Wilcoxon test. There were 6 mice in each group. Data are representative of 3 separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal